News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CEO Highlights How Chronix Biomedical's Unique Blood Tests Can Enable Early Cancer Diagnosis and Personalized Treatment at Payor Oncology Conference


11/16/2010 10:24:40 AM

BALTIMORE & SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced that its Chief Executive Officer, Dr. Howard Urnovitz, is presenting a session on “Improving Technology for Cancer Detection and Screening” at the Payor Oncology Management Summit, a conference for healthcare insurers and providers focusing on new developments in cancer diagnosis, treatment and prevention. Chronix is developing disease-specific epigenomic biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix‘s serum tests are applicable to a wide range of cancers and other chronic diseases.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES